Janux Announced Updated Interim Clinical Data For JANX007 Clinical Program
Janux Announced Updated Interim Clinical Data For JANX007 Clinical Program
Janux宣佈了關於JANX007臨床項目的最新中期臨床數據
- Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO 2L / 3L patients
-
In 16 patients JANX007 displayed:
- High PSA response rates: 100% achieved best PSA50 declines
- Deep PSA declines: 63% achieved best PSA90 declines; 31% achieved best PSA99 declines
- Durable PSA response at ≥ 12 weeks: 75% maintained PSA50 declines; 50% maintained PSA90 declines
- Encouraging anti-tumor activity: 50% ORR (4/8) and 63% DCR (5/8)
- Well-tolerated safety profile: CRS and TRAEs primarily limited to cycle 1 and grades 1 and 2; Maximum tolerable dose has not yet been reached
- Janux to host virtual investor event today at 4:30 PM Eastern Time
- 新興的JANX007數據在5L mCRPC患者中顯示出顯著的臨床活性，支持針對預PLUVICTO 2L / 3L患者的臨床開發計劃
- 在16名患者中，JANX007顯示出了：
- 高PSA反應率：100%實現最佳PSA50下降
- 深度PSA下降：63%實現最佳PSA90下降；31%實現最佳PSA99下降
- 在≥12周時持久的PSA反應：75%維持PSA50下降；50%維持PSA90下降
- 令人鼓舞的抗腫瘤活性：50% ORR (4/8) 和63% DCR (5/8)
- 良好的耐受性安全性特徵：CRS和TRAEs主要限制在週期1和1級及2級；尚未達到最大耐受劑量
- Janux將在今天東部時間下午4:30舉辦虛擬投資者活動
資訊熱榜
更新時間